Short Interest in Cryo-Cell International, Inc. (NYSEAMERICAN:CCEL) Drops By 5.9%

Cryo-Cell International, Inc. (NYSEAMERICAN:CCEL) was the target of a significant decline in short interest in December. As of December 15th, there was short interest totalling 19,000 shares, a decline of 5.9% from the November 30th total of 20,200 shares. Based on an average daily volume of 19,600 shares, the short-interest ratio is currently 1.0 days. Currently, 0.6% of the shares of the stock are short sold.

Institutional Inflows and Outflows

An institutional investor recently raised its position in Cryo-Cell International stock. Geode Capital Management LLC boosted its stake in Cryo-Cell International, Inc. (NYSEAMERICAN:CCEL) by 68.5% in the 3rd quarter, according to its most recent filing with the SEC. The fund owned 39,860 shares of the company’s stock after purchasing an additional 16,203 shares during the period. Geode Capital Management LLC owned about 0.49% of Cryo-Cell International worth $254,000 at the end of the most recent quarter. Hedge funds and other institutional investors own 10.44% of the company’s stock.

Cryo-Cell International Stock Performance

CCEL opened at $7.41 on Thursday. The company has a market capitalization of $59.72 million, a price-to-earnings ratio of -6.99 and a beta of 0.49. Cryo-Cell International has a 1-year low of $4.47 and a 1-year high of $9.50.

Cryo-Cell International (NYSEAMERICAN:CCEL) last posted its quarterly earnings results on Tuesday, October 15th. The company reported $0.13 EPS for the quarter, topping the consensus estimate of $0.02 by $0.11. Cryo-Cell International had a negative return on equity of 42.06% and a negative net margin of 28.03%. The business had revenue of $8.07 million for the quarter.

Cryo-Cell International Dividend Announcement

The company also recently declared a — dividend, which was paid on Friday, November 29th. Stockholders of record on Friday, November 15th were paid a $0.25 dividend. The ex-dividend date of this dividend was Friday, November 15th. Cryo-Cell International’s dividend payout ratio (DPR) is -94.34%.

Cryo-Cell International Company Profile

Cryo-Cell International, Inc engages in the cellular processing and cryogenic cellular storage with a focus on the collection and preservation of umbilical cord blood stem cells for family use. It provides cord tissue service that stores a section of the umbilical cord tissue, a source of mesenchymal stem cells that are used in regenerative medicine to treat a range of conditions, including heart, and kidney disease, ALS, wound healing, auto-immune diseases, multiple sclerosis, Alzheimer's disease, Parkinson's diseases.